Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison

P Moreau, B Hebraud, T Facon, X Leleu, C Hulin, M Hashim, Y Hu, D Caillot, L Benboubker, S Zweegman, M Merz, K Weisel, H Salwender, EK Mai, H Goldschmidt, U Bertsch, V Vanquickelberghe, T Kampfenkel, CD Boer, S KrotnevaI Proskorovsky, J He, A Lam, C Lee, S Cote, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients and methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). Results: After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. Conclusion: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.

Original languageEnglish
Pages (from-to)143-154
Number of pages12
JournalImmunotherapy
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2021

Research programs

  • EMC OR-01

Fingerprint

Dive into the research topics of 'Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: Matching-adjusted indirect comparison'. Together they form a unique fingerprint.

Cite this